{"id":"sirolimus-maraviroc","safety":{"commonSideEffects":[{"rate":null,"effect":"Immunosuppression"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus inhibits the mTOR pathway, reducing T-cell and B-cell proliferation and promoting regulatory T-cell differentiation. Maraviroc blocks the CCR5 chemokine receptor on CD4+ T cells, preventing R5-tropic HIV entry. Together, they aim to reduce viral load while modulating immune activation in HIV-infected patients.","oneSentence":"This combination uses sirolimus (an mTOR inhibitor) to suppress immune cell proliferation and maraviroc (a CCR5 antagonist) to block HIV entry, together targeting both viral replication and immune dysregulation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:45.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (R5-tropic virus)"}]},"trialDetails":[{"nctId":"NCT02990312","phase":"PHASE4","title":"Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2017-05-01","conditions":"Hiv, Kidney Transplant, HIV Reservoir","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rapamycin","Rapamune","Selzentry"],"phase":"marketed","status":"active","brandName":"Sirolimus + Maraviroc","genericName":"Sirolimus + Maraviroc","companyName":"University of Maryland, Baltimore","companyId":"university-of-maryland-baltimore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses sirolimus (an mTOR inhibitor) to suppress immune cell proliferation and maraviroc (a CCR5 antagonist) to block HIV entry, together targeting both viral replication and immune dysregulation. Used for HIV-1 infection (R5-tropic virus).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}